Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that was approved for postmenopausal osteoporosis in 2019 and ...

The trio includes two bone-building bispecific antibodies – sclerostin and DKK1-targeting AGA2118 and AGA2115 for osteoporosis and brittle bone disease (osteogenesis imperfecta), respectively ...

During OTM, periodontal fibroblasts secrete PTHrP, which inhibits sclerostin secretion in neighboring osteocytes via the PTH/PTHrP type 1 receptor interaction. The ensuing sclerostin-depleted region ...

Ankylosing spondylitis (AS) can increase your risk of developing osteoporosis. Some lifestyle changes may help delay or prevent its development. AS is a chronic, inflammatory condition that causes ...

The development of precise and efficient delivery systems is pivotal for advancing CRISPR/Cas9 gene-editing technologies, particularly for therapeutic applications. Engineered metal–organic frameworks ...

MGP (matrix Gla protein) inhibits arterial calcification. Higher inactive MGP, in its dephosphorylated‐uncarboxylated (dp‐uc) form, is positively associated with vascular calcification, possibly ...

2162.HK Keymed Biosciences Inc.

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and ...

The past decade has seen significant advances in our understanding of skeletal homeostasis and the mechanisms that mediate the loss of bone integrity in disease. Recent breakthroughs have arisen ...